Patents by Inventor Derek Wheeler
Derek Wheeler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11065195Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.Type: GrantFiled: February 27, 2019Date of Patent: July 20, 2021Assignee: MC2 Therapeutics LimitedInventors: Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
-
Publication number: 20210000796Abstract: There is provided a topical formulation comprising a nucleophile, such as amino acids and most polypetides and/or a derivative thereof, for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject. The amino acid may be histidine and the derivative may be a histidine degradation product, a peptide of histidine, a peptide of histidine and one or more additional amino acids, and a pharmaceutically-acceptable salt of histidine.Type: ApplicationFiled: September 18, 2020Publication date: January 7, 2021Applicant: DRUG DELIVERY SOLUTIONS APSInventors: Torkil MENNE, Johan SELMER, Jesper LANGE, Michelle GEORGIOU, Derek WHEELER, David EVANS
-
Patent number: 10806721Abstract: There is provided a topical formulation comprising a nucleophile, such as amino acids and most polypeptides and/or a derivative thereof, for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject. The amino acid may be histidine and the derivative may be a histidine degradation product, a peptide of histidine, a peptide of histidine and one or more additional amino acids, and a pharmaceutically-acceptable salt of histidine.Type: GrantFiled: June 16, 2017Date of Patent: October 20, 2020Assignee: DRUG DELIVERY SOLUTIONS APSInventors: Torkil Menne, Johan Selmer, Jesper Lange, Michelle Georgiou, Derek Wheeler, David Evans
-
Publication number: 20190358151Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.Type: ApplicationFiled: February 27, 2019Publication date: November 28, 2019Applicant: DRUG DELIVERY SOLUTIONS LIMITEDInventors: Derek WHEELER, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
-
Publication number: 20190321336Abstract: There is provided a topical formulation comprising a nucleophile, such as amino acids and most polypeptides and/or a derivative thereof, for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject. The amino acid may be histidine and the derivative may be a histidine degradation product, a peptide of histidine, a peptide of histidine and one or more additional amino acids, and a pharmaceutically-acceptable salt of histidine.Type: ApplicationFiled: June 16, 2017Publication date: October 24, 2019Inventors: Torkil MENNE, Johan SELMER, Jesper LANGE, Michelle GEORGIOU, Derek WHEELER, David EVANS
-
Patent number: 10265265Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analog and at least one corticosteroid.Type: GrantFiled: March 14, 2008Date of Patent: April 23, 2019Assignee: DRUG DELIVERY SOLUTIONS LIMITEDInventors: Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
-
Patent number: 8603503Abstract: A biliquid foam includes from 10% to 98% by weight of a non-polar liquid other than a fuel and from 2 to 88% by weight of a continuous phase polar liquid comprising a C1-C4 alcohol, a liquid polyethylene glycol, ethylene glycol or propylene glycol, or mixtures thereof, in an amount of at least 65% by weight, relative to the weight of the continuous phase, wherein the biliquid foam is stabilized with an amount of from 0.05% to 2% by weight based on the total formulation of a surfactant which is selected from castor oil/poly(alkylene glycol) adducts containing from 20 to 50 alkoxy groups, a C8-C24 fatty acid or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof.Type: GrantFiled: July 30, 2004Date of Patent: December 10, 2013Assignee: Drug Delivery Solutions LimitedInventors: Monica Dias, Philip Guffogg, Derek Wheeler, Mark Whitbread-Jordan
-
Patent number: 8008356Abstract: A polyaphron dispersion comprising an external phase and polyaphrons having an internal phase, the internal phase comprising (i) a first phase which is liquid and (ii) a second phase which is liquid or gaseous.Type: GrantFiled: February 24, 2005Date of Patent: August 30, 2011Assignee: Drug Delivery Solutions LimitedInventors: Andrew Childs, Derek Wheeler
-
Publication number: 20100093676Abstract: A topical composition comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion and at least one vitamin D or vitamin D analogue.Type: ApplicationFiled: March 14, 2008Publication date: April 15, 2010Inventors: Derek A. Wheeler, David F. Steele
-
Publication number: 20080234239Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.Type: ApplicationFiled: March 14, 2008Publication date: September 25, 2008Inventors: Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
-
Publication number: 20080227759Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.Type: ApplicationFiled: September 27, 2007Publication date: September 18, 2008Inventors: Derek Wheeler, Steen Sindet-Pedersen, David F. Steele, Michelle Georgiou
-
Publication number: 20070190088Abstract: A polyaphron dispersion comprising an external phase and polyaphrons having an internal phase, the internal phase comprising (i) a first phase which is liquid and (ii) a second phase which is liquid or gaseous.Type: ApplicationFiled: February 24, 2005Publication date: August 16, 2007Inventors: Andrew Childs, Derek Wheeler
-
Publication number: 20070161527Abstract: A solid composition comprising oil core aphrons dispersed in a solid surfactant.Type: ApplicationFiled: January 18, 2005Publication date: July 12, 2007Inventors: Anthony Mercurio, Derek Wheeler
-
Publication number: 20070071684Abstract: A method of coating the surface of a substrate which comprises the steps of: i) contacting the surface with a polymerisable mixture comprising one or more polymerisable components and containing suspended droplets of a biliquid foam or of a high internal oil phase emulsion, the said droplets being stabilised by a non-reactive surfactant; and ii) polymerising the coating to form a polymer comprising the droplets entrapped therein.Type: ApplicationFiled: September 23, 2004Publication date: March 29, 2007Inventors: Nigel Crutchley, James Guthrie, Derek Wheeler, Stephen Lenon
-
Publication number: 20060239947Abstract: A biliquid foam comprising from 10% to 98% by weight of a non-polar liquid other than a fuel and from 2 to 88% by weight of a continuous phase polar liquid comprising a C1-C4 alcohol, a liquid polyethylene glycol, ethylene glycol or propylene glycol, or mixtures thereof, in an amount of at least 65% by weight, relative to the weight of the continuous phase, wherein the biliquid foam is stabilized with an amount of from 0.05% to 2% by weight based on the total formulation of a surfactant which is selected from castor oil/poly(alkylene glycol) adducts containing from 20 to 50 alkoxy groups, a C8-C24 fatty acid or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof. A stable dispersion having a content of at least 65% by weight with regard to C1-C4 alcohol, liquid polyethylene glycol, ethylene glycol or propylene glycol which dispersion comprises from 1-80% by weight of a biliquid foam and from 99-20% by weight of an aqueous gel.Type: ApplicationFiled: July 30, 2004Publication date: October 26, 2006Inventors: Monica Dias, Philip Guffogg, Derek Wheeler, Mark Whitebread-Jordan
-
Publication number: 20060228408Abstract: An oral drug delivery system which comprises a biliquid foam comprising: from 1 to 20% by weight of a continuous hydrophilic phase, from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase, the said pharmaceutically acceptable oil having dissolved or dispersed therein a poorly water-soluble drug in an amount of from 0.1 to 20% by weight and the biliquid foam including therein from 0.5 to 10% by weight of a surfactant to enable the formation of a stable biliquid foam, all percentages being based upon the total weight of the formulation.Type: ApplicationFiled: July 30, 2004Publication date: October 12, 2006Inventors: William Charman, Monica Dias, Michelle Georgiou, Philip Guffogg, Christopher Porter, Colin Pouton, Fraser Steele, Derek Wheeler
-
Publication number: 20050097812Abstract: A fuel composition which comprises a biliquid foam consisting of from 10% to 97.5% by weight of non-coalescing droplets of a non-polar liquid comprising a petroleum derivative, paraffin or a liquid halogenated hydrocarbon and from 2 to 87% by weight of a continuous phase polar liquid comprising a C1-C3 alcohol, a C4 alcohol containing at least two hydroxy groups, or ethylene glycol, or mixtures thereof, in an amount of from 60% to 100% by weight thereof, wherein the biliquid foam is stabilized with an amount of from 0.5 to 3.0% by weight based on the total formulation of a surfactant which is selected from castor oil/poly(alkylene glycol) adducts containing from 20 to 50 alkoxy groups, or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof.Type: ApplicationFiled: January 31, 2003Publication date: May 12, 2005Applicant: DISPERSE LIMITEDInventors: Philip Guffogg, Stephen Lenon, Derek Wheeler
-
Publication number: 20050049315Abstract: A method for the preparation of a biliquid foam which does not rely upon the initial formation of a gas foam, in which a stirrer having a single or a multiplicity of blades is used, the stirrer being operated in a manner such that at least one part of the stirrer mechanism breaks the interface between the continuous polar phase used to form the biliquid foam and the air, the non-polar phase being added dropwise at least initially whilst stirring the continuous polar phase and the rate of addition of the non-polar phase being controlled so that a biliquid foam composition is formed.Type: ApplicationFiled: January 31, 2003Publication date: March 3, 2005Inventors: Philip Guffogg, Derek Wheeler